At a glance
ClinicalIndex Comparison RecordN/ACompleted· 206 enrolled
Drug / intervention
RPS InflammaDry Detector™device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Clinical Evaluation of the RPS InflammaDry Detector's Sensitivity and Specificity Compared to the Clinical Diagnosis for Confirming Dry Eyes.
In Brief
An observational study evaluating RPS InflammaDry Detector™ for Dry Eye. Completed, enrolled 206 participants across 8 sites.
Detailed Summary
The RPS InflammaDry Detector™ is intended to detect elevated MMP-9 in human tears to aid in the diagnosis of patients with signs or symptoms of dry eye disease, in conjunction with other methods of clinical evaluation.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2010
First PostedMar 2011
Primary CompletionOct 2011
TodayJul 2026
First PostedMar 11, 2011
Enrollment StartNov 1, 2010
Primary CompletionOct 1, 2011
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 15.3 years ago
Interventions
RPS InflammaDry Detector™device
A noninvasive immunoassay for detecting MMP-9 levels in tears